Dublin, June 08, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/sg...bal_orphan ) has announced the addition of the "Global Orphan Drug Market Future Outlook 2020" report to their offering. In recent years, several new rare diseases are being included in clinical trials for the development of orphan drug candidate. Oncology, Genetic diseases, Autoimmune, pulmonary disease, Central nervous system and others are main focus of orphan drug developers. All of these diseases have large patient base but their rare forms doesn't have suitable therapeutics which reflects the marketing potential of orphan drugs in these segments.
Out of these, oncology segment has got maximum attention followed by rare genetic disorders, neurological disorder and autoimmune disorders. In a bigger view, orphan drug segment is expected to grow several folds in coming years due to several favorable factors. Introduction of innovative technologies, favorable pricing, reimbursement, unmet medical necessities and strong clinical pipeline could be attributed as important factors responsible for their growth. "Global Orphan Drug Market Future Outlook 2020" report highlights: - Global Orphan Drug Market Overview - Global Orphan Drug Market Segment Analysis - FDA & EMA Regulation for Clinical Trials Orphan Designated Drugs - Orphan Drug Designation Criteria & Reimbursement Policy by Region - Comprehensive Insight on Global Orphan Drugs Clinical Pipeline & Patent Analysis by Company, Country, Indication & Phase - Global Orphan Drugs Clinical Pipeline: 697 Drugs - Majority Orphan Drugs in Phase-II Trials: 249 Drugs - Marketed Orphan Drugs: 274 Drugs Key Topics Covered: 1. Introduction to Orphan Drug 2. Favorable Market Dynamics for Orphan Drugs Commercialization 3. Global Orphan Drug Market Overview 4. Global Orphan Drug Market Segment Analysis 5. Global Orphan Drug Clinical Pipeline Overview 6. US Orphan Drug Market Overview 7. Europe Orphan Drug Market Overview 8. Asia Orphan Drug Market Overview 9. FDA Regulation for Clinical Trials Orphan Designated Drugs 10. EMA Regulations for Clinical Trials of Orphan Designated Drugs 11. Asian Regulations for Clinical Trials of Orphan Designated Drugs 12. Global Orphan Drugs Clinical Pipeline Insight & Patent Analysis by Company, Country, Indication & Phase 13. Marketed Orphan Drugs Clinical Insight & Patent Analysis by Company, Country & Indication 14. Discontinued & Suspended Orphan Drugs in Clinical Trials 15. Competitive Landscape - AOP Orphan - Agenus - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Genethon - Genzyme Corporation - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Orphan Europe - Pfizer - Prosensa - Rare Disease Therapeutics - Roche - Sanofi - Shire - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/sg...bal_orphan
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Pharmaceuticals